Brady W. Dougan - Jan 21, 2025 Form 4 Insider Report for Humacyte, Inc. (HUMA)

Role
Director
Signature
/s/ Brady W. Dougan by Dale A. Sander as Attorney-in-Fact
Stock symbol
HUMA
Transactions as of
Jan 21, 2025
Transactions value $
$0
Form type
4
Date filed
1/23/2025, 04:34 PM
Previous filing
Dec 20, 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HUMA Stock Options (right to buy) Award $0 +1.13M $0.00 1.13M Jan 21, 2025 Common Stock 1.13M $4.56 By spouse F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The first 25% of the option becomes exercisable on January 21, 2026, after which 1/48 of the option will become exercisable on the 21st of each month through January 21, 2029.